不同剂量瑞舒伐他汀在急性冠脉综合征经皮冠状动脉介入治疗术后患者中的临床效果

Clinical effects of different doses of rosuvastatin in patients with acute coronary syndrome after percutaneous coronary intervention

目的探讨急性冠脉综合征患者经皮冠状动脉介入(PCI)治疗术后采用不同剂量瑞舒伐他汀治疗的临床效果。方法将2013年1月至2015年1月我院心血管内科收治的300例行经皮冠状动脉介入治疗的急性冠脉综合征患者根据治疗方式不同分为三组,每组100例。A组患者给予5 mg/d瑞舒伐他汀治疗,B组给予10 mg/d瑞舒伐他汀治疗,C组给予20 mg/d瑞舒伐他汀治疗。比较三组患者的临床效果。结果治疗后,三组患者hs-CRP、BNP、TC、TG、HDL-C、LDL-C水平均较治疗前明显改善(P<0.05),C组患者hs-CRP、BNP、TC、TG、LDL-C水平明显优于A组和B组(P<0.05);三组患者不良反应发生率及心脑血管事件发生率比较,差异无统计学意义(P>0.05)。结论急性冠脉综合征患者介入治疗后采用高剂量瑞舒伐他汀治疗能有效减轻患者的炎性反应,改善心功能和血脂水平,且不增加不良反应,安全性高,具有较高的临床应用价值。

Objective To investigate the clinical effects of different doses of rosuvastatin in patients with acute coronarysyndrome after percutaneous coronary intervention （PCI）. Methods A total of 300 patients with acute coronary syndromeafter PCI admitted in our hospital from January 2013 to January 2015 were selected and divided into three groupsaccording to the treatment methods, with 100 cases in each group. Group A was given5 mg/d rosuvastatin, groupB wasgiven 10 mg/d rosuvastatin, group C received 20 mg/d rosuvastatin. The clinical effects were compared among the threegroups. Results After treatment, the levels of hs-CRP, BNP, TC, TG, HDL-C and LDL-C in the three groups were betterthan those before treatment（P约0.05）, and hs-CRP, BNP, TC, TG LDL-C of the groupC were better than those of the groupA and group B（P约0.05）. There were no significant differences in incidences of adverse reactions and cardiovascular eventsamong the three groups（P跃0.05）. Conclusion High dose of rosuvastatin in patients with acute coronary syndrome after PCIcan effectively reduce the inflammatory response of the patient , improve the cardiac function and the blood lipid level,does not increase the adverse reaction and has high safety, which has higher clinical application value.